Increased expression of fibroblast growth factor receptor 3 in
CD34+ BCR-ABL+ cells from patients with chronic myeloid
leukemia

J 2003

Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia

DVOŘÁK, Petr, Aleš HAMPL, D. DVOŘÁKOVÁ, M. DOUBEK, J. FAITOVÁ et. al.

Základní údaje

Originální název

Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia

Autoři

DVOŘÁK, Petr, Aleš HAMPL, D. DVOŘÁKOVÁ, M. DOUBEK, J. FAITOVÁ, L. PACHOLÍKOVÁ a J. MAYER

Vydání

Leukemia, 2003, 0887-6924

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

Genetika a molekulární biologie

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 5.116

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

cells

Štítky

cells

Změněno: 1. 2. 2006 13:45, prof. Ing. Petr Dvořák, CSc.

Anotace

V originále

Previously, we showed that expression of myeloma-associated (proto)oncogene fibroblast growth factor receptor 3 (FGFR-3) is increased in white blood cells from patients with chronic myeloid leukemia (CML). The abnormal expression was returned back to the normal levels as soon as these patients reconstituted their hematopoiesis following transplantation of allogeneic peripheral blood stem cells. The aims of this study were: (1) to define population(s) of cells overexpressing FGFR-3, and (2) to determine the expression of FGFR-3 during the clinical course of the disease. We show that the vast majority of FGFR-3 transcripts as well as FGFR-3 protein arise from CD34+ BCR-ABL+ cells. Although increased levels of FGFR-3 were found in majority of late chronic phase patients treated with interferon alpha or hydroxyurea, the expression of FGFR-3 was always lowered following treatment with BCR-ABL tyrosine kinase inhibitor STI571. Compared to unstimulated cells, high levels of FGFR-3 were also identified in CD34+ cells from granulocyte colony-stimulating factor-mobilized blood stem cell harvests from healthy donors, suggesting a potential growth factor-dependent basis for elevated expression of FGFR-3 in CML. These findings have implications for the involvement of FGFR-3 in malignant hematopoiesis and depict FGFR-3 tyrosine kinase in CD34+ leukemic cells as a possible target for tyrosine kinase inhibitors.

Citovat

DVOŘÁK, Petr, Aleš HAMPL, D. DVOŘÁKOVÁ, M. DOUBEK, J. FAITOVÁ, L. PACHOLÍKOVÁ a J. MAYER. Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia. Leukemia. 2003, roč. 17, č. 12, s. 2418-2425. ISSN 0887-6924.

@article{618032,
   author = {Dvořák, Petr and Hampl, Aleš and Dvořáková, D. and Doubek, M. and Faitová, J. and Pacholíková, L. and Mayer, J.},
   article_number = {12},
   keywords = {cells},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia},
   volume = {17},
   year = {2003}
}

TY  - JOUR
ID  - 618032
AU  - Dvořák, Petr - Hampl, Aleš - Dvořáková, D. - Doubek, M. - Faitová, J. - Pacholíková, L. - Mayer, J.
PY  - 2003
TI  - Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia
JF  - Leukemia
VL  - 17
IS  - 12
SP  - 2418-2425
EP  - 2418-2425
SN  - 08876924
KW  - cells
N2  - Previously, we showed that expression of myeloma-associated (proto)oncogene fibroblast growth factor receptor 3 (FGFR-3) is increased in white blood cells from patients with chronic myeloid leukemia (CML). The abnormal expression was returned back to the normal levels as soon as these patients reconstituted their hematopoiesis following transplantation of allogeneic peripheral blood stem cells. The aims of this study were: (1) to define population(s) of cells overexpressing FGFR-3, and (2) to determine the expression of FGFR-3 during the clinical course of the disease. We show that the vast majority of FGFR-3 transcripts as well as FGFR-3 protein arise from CD34+ BCR-ABL+ cells. Although increased levels of FGFR-3 were found in majority of late chronic phase patients treated with interferon alpha or hydroxyurea, the expression of FGFR-3 was always lowered following treatment with BCR-ABL tyrosine kinase inhibitor STI571. Compared to unstimulated cells, high levels of FGFR-3 were also identified in CD34+ cells from granulocyte colony-stimulating factor-mobilized blood stem cell harvests from healthy donors, suggesting a potential growth factor-dependent basis for elevated expression of FGFR-3 in CML. These findings have implications for the involvement of FGFR-3 in malignant hematopoiesis and depict FGFR-3 tyrosine kinase in CD34+ leukemic cells as a possible target for tyrosine kinase inhibitors.
ER  -

DVOŘÁK, Petr, Aleš HAMPL, D. DVOŘÁKOVÁ, M. DOUBEK, J. FAITOVÁ, L. PACHOLÍKOVÁ a J. MAYER. Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia. \textit{Leukemia}. 2003, roč.~17, č.~12, s.~2418-2425. ISSN~0887-6924.

Podrobný výpis o publikaci